Tiny Mabion Races Big Pharma To EU Rituximab Market

Poland’s biotech Mabion is racing to the European biosimilar market with a biosimilar rituximab, but is up against multinational biosimilar companies like Sandoz and South Korea’s Celltrion, and will likely need a strong commercialization partner outside its home market.

Maciej Wieczorek
Mabion's President Maciej Wieczorek • Source: Mabion SA

Poland’s fledgling biotech company, Mabion SA, believes it is among the leaders in the race to develop a biosimilar version of Roche's monoclonal antibody, MabThera/Rituxan (rituximab), for Europe, but it needs to finalize a tie-up with a marketing partner or partners fast, as they will need time to prepare to compete against biosimilar heavyweights that are also developing versions of the blockbuster TNF-inhibitor.

Mabion expects to administer the last doses of its biosimilar rituximab, MabionCD20, in pivotal clinical studies this summer – in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category